
BIO-key International Files S-1 for Resale of 1.24M Shares
BIO-key International, Inc. has filed an S-1 registration statement amendment for the resale of up to 1,236,668 shares of common stock by a selling stockholder, Armistice Capital Master Fund Ltd. These shares are issuable upon the exercise of warrants. The company will not receive proceeds from this resale, but would receive approximately $5.02 million if all warrants are exercised for cash. The filing also details the company's identity access management platform and strategic outlook, including plans for market expansion and potential acquisitions.
Key Highlights
- BIO-key International, Inc. files S-1 amendment for resale of 1,236,668 shares of common stock by selling stockholder.
- Selling stockholder, Armistice Capital Master Fund Ltd., may sell shares issuable upon exercise of warrants.
- Company will not receive proceeds from the resale; potential $5.02M cash proceeds if warrants exercised for cash.
- Warrants have an exercise price of $4.06 per share and expire on October 30, 2031.
- Company operates as a leading identity access management (IAM) platform provider.
- Strategic outlook includes expanding market share in government, higher education, and financial services.
- Company is pursuing strategic acquisitions in the IAM space.
Price Impact
More from BKYI
BIO-key International Reports Q3 2026 Results: Revenue Down Slightly, Net Loss Improves Year-to-Date
BIO-key Q3 License Fees Up 39%; Net Loss Narrows 8%
BIO-key International Files S-1 Amendment for Warrant Resale